Goldman raised the price target for the TG Therapeutics Inc. (NASDAQ:TGTX) stock to “a Neutral”. The rating was released on April 20, 2021. We previously noted in another research note published on April 19, 2021 by H.C. Wainwright that reiterated the stock to a Buy with a price target of $89 for TGTX stock. The research report from JP Morgan has initiated the stock to Overweight, with a price target set at $38. The stock was reiterated by H.C. Wainwright, who disclosed in a research note on August 11, 2020, to Buy and set the price objective to $38. In their research brief published June 05, 2020, Evercore ISI analysts initiated the TG Therapeutics Inc. stock to Outperform with a price target of $60.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.71 during the last quarter as opposed to a consensus estimate of -$0.58, which indicates the company missed its estimate by -$0.13, which implies that the company surprised the market by -22.40%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.49. This is an average of 6 analysts’ earnings, where the high earnings per share estimate is -$0.35 and the low earnings per share estimate is -$0.65.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of TG Therapeutics Inc. (NASDAQ:TGTX) raised 3.93% to close Friday’s market session at $44.71, higher as compared to yesterday’s close. The stock price fluctuated between $43.4001 and $45.28 throughout the trading session with the volume trading being 1594541 shares, which represented a significant variation when compared to the three months average volume of 1.48 million shares. The firm’s stock price fluctuated 5.42% within the last five trades and -7.24% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 72.56% in the last 6 months and -7.38% was subtracted to its value over the previous 3 months. TGTX stock is trading at a margin of 0.95%, -1.25% and 23.31% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, TGTX deals in the Healthcare domain. The stock is trading -21.20 percent below its 52-week high and 312.83 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 66.81. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does TG Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $6.09 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 30449.74 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 10.70, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 9.90 percent of TG Therapeutics Inc. shares are owned by insiders, and 75.60 percent are held by financial institutions. Echelard Yann, the Director at TG Therapeutics Inc. (TGTX) has sold 30,000 shares of firm on Dec 10 at a price of $40.05 against the total amount of $1.2 million. In another inside trade, RA CAPITAL MANAGEMENT, L.P., 10% Owner of TG Therapeutics Inc. (NASDAQ:TGTX) sold 158,589 shares of the firm on Sep 09 for a total worth of $4.09 million at a price of $25.81. An inside trade which took place on Jun 17, Director of TG Therapeutics Inc. KENNEDY WILLIAM JAMES sold 7,745 shares of firm against total price of $0.14 million at the cost of $18.27 per share.